ATCC wins $99m DOW contract to manage military medical countermeasures

ATCC, the Virginia-based biological materials nonprofit, has been awarded a 10-year contract worth up to $99 million by the US Department of War (DOW) to coordinate lifecycle management of military medical countermeasures (MCMs). The award positions ATCC as prime contractor for the Rapid Access to Products in Development (RAPID) programme, which is tasked with ensuring government-owned vaccines, biologics and drugs remain viable and deployable against chemical and biological threats across the Joint Force.

RAPID sits under the Joint Project Lead for Chemical, Biological, Radiological and Nuclear Enabling Technologies, itself part of the Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense. The programme's remit covers supply chain integrity, ongoing testing infrastructure, and the regulatory upkeep required to keep MCMs ready for fielding at short notice.

The contract and ATCC's role

Rebecca Bradford, senior vice president of ATCC Federal Solutions, framed readiness as the central challenge. "Medical countermeasures are only as valuable as our ability to deploy them when and where they are needed," she said. "The RAPID programme ensures that the supply chain and ongoing testing infrastructure behind those countermeasures is solid, so when our warfighters need protection, it is there."

ATCC says it holds more than 40 active federal contracts and has previously supported surge responses across Influenza, COVID-19, Zika, Yellow Fever and Ebola. Its existing DOW relationships include programmes with the Walter Reed Army Institute of Research and the Defense Advanced Research Projects Agency, the latter focused on biomanufacturing research aimed at reducing military reliance on petrochemicals. Antimicrobial resistance support for WRAIR is also listed among its current activities.

Market and regulatory context

The award reflects a broader push by the US government to shore up the domestic MCM supply chain following scrutiny of preparedness gaps exposed during the COVID-19 pandemic. BARDA, NIH and the CDC have all expanded their contractor bases in recent years, and the DOW has similarly sought to formalise relationships with organisations capable of spanning scientific, regulatory and logistics functions simultaneously.

ATCC's status as a 501(c)3 nonprofit and its century-long stewardship of biological reference materials give it a particular standing in federal procurement, where trust in chain-of-custody for sensitive biological materials is a significant differentiator. Commercial life sciences companies with bioprocessing and biologics manufacturing capabilities have also competed in this space, but the combination of authenticated cell-line collections, regulatory expertise and established federal relationships that ATCC brings is not easily replicated by a commercial entrant in a short timeframe.

For the biologics and bioprocessing sectors more broadly, contracts of this kind signal sustained government demand for organisations that can bridge laboratory-scale biological material management with GMP-compliant supply chain operations. The 10-year duration provides an unusual degree of visibility, suggesting the DOW views RAPID as a long-term structural capability rather than a short-cycle procurement exercise.

ATCC is headquartered in Manassas, Virginia, with research centres in Gaithersburg and Germantown, Maryland. The contract is funded under Agreement W911SR-26-9-A017.